These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37300571)

  • 1. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.
    Jovalekic A; Roé-Vellvé N; Koglin N; Quintana ML; Nelson A; Diemling M; Lilja J; Gómez-González JP; Doré V; Bourgeat P; Whittington A; Gunn R; Stephens AW; Bullich S
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3276-3289. PubMed ID: 37300571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing the centiloid transformation for
    Bourgeat P; Doré V; Fripp J; Ames D; Masters CL; Salvado O; Villemagne VL; Rowe CC;
    Neuroimage; 2018 Dec; 183():387-393. PubMed ID: 30130643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of
    Doré V; Bullich S; Rowe CC; Bourgeat P; Konate S; Sabri O; Stephens AW; Barthel H; Fripp J; Masters CL; Dinkelborg L; Salvado O; Villemagne VL; De Santi S
    Alzheimers Dement; 2019 Jun; 15(6):807-816. PubMed ID: 31101517
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Rowe CC; Doré V; Jones G; Baxendale D; Mulligan RS; Bullich S; Stephens AW; De Santi S; Masters CL; Dinkelborg L; Villemagne VL
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2053-2059. PubMed ID: 28643043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
    Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Software compatibility analysis for quantitative measures of [
    Pemberton HG; Buckley C; Battle M; Bollack A; Patel V; Tomova P; Cooke D; Balhorn W; Hegedorn K; Lilja J; Brand C; Farrar G
    EJNMMI Res; 2023 May; 13(1):48. PubMed ID: 37225974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.
    Bourgeat P; Doré V; Burnham SC; Benzinger T; Tosun D; Li S; Goyal M; LaMontagne P; Jin L; Rowe CC; Weiner MW; Morris JC; Masters CL; Fripp J; Villemagne VL;
    Neuroimage; 2022 Nov; 262():119527. PubMed ID: 35917917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized classification of
    Bullich S; Seibyl J; Catafau AM; Jovalekic A; Koglin N; Barthel H; Sabri O; De Santi S
    Neuroimage Clin; 2017; 15():325-332. PubMed ID: 28560157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance in detecting amyloid positivity between
    Cho SH; Choe YS; Kim YJ; Lee B; Kim HJ; Jang H; Kim JP; Jung YH; Kim SJ; Kim BC; Farrar G; Na DL; Moon SH; Seo SW
    Sci Rep; 2020 Nov; 10(1):19576. PubMed ID: 33177593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of simulated reduced injected dose on the assessment of amyloid PET scans.
    Young P; Heeman F; Axelsson J; Collij LE; Hitzel A; Sanaat A; Niñerola-Baizan A; Perissinotti A; Lubberink M; Frisoni GB; Zaidi H; Barkhof F; Farrar G; Baker S; Gispert JD; Garibotto V; Rieckmann A; Schöll M;
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):734-748. PubMed ID: 37897616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
    Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
    Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET.
    Kim SJ; Ham H; Park YH; Choe YS; Kim YJ; Jang H; Na DL; Kim HJ; Moon SH; Seo SW
    Alzheimers Res Ther; 2022 Oct; 14(1):157. PubMed ID: 36266688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [
    Bucci M; Savitcheva I; Farrar G; Salvadó G; Collij L; Doré V; Gispert JD; Gunn R; Hanseeuw B; Hansson O; Shekari M; Lhommel R; Molinuevo JL; Rowe C; Sur C; Whittington A; Buckley C; Nordberg A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2183-2199. PubMed ID: 33844055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of early-phase [
    Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
    Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Amyloid positron-emission-tomography with [
    Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
    Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer's disease preclinical phase evaluated by dual-phase
    Kim GH; Kim BR; Yoon HJ; Jeong JH
    Sci Rep; 2024 Aug; 14(1):18480. PubMed ID: 39122860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility evaluation of middle-phase
    Wu CH; Lu YH; Lee TH; Tu CY; Fuh JL; Wang YF; Yang BH
    Quant Imaging Med Surg; 2023 Aug; 13(8):4806-4815. PubMed ID: 37581034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.